Creative Medical Technology
CELZ
10 hedge funds and large institutions have $214K invested in Creative Medical Technology in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 0 closing their positions.
11% more funds holding
Funds holding: 9 → 10 (+1)
0.03% more ownership
Funds ownership: 5.14% → 5.16% (+0.03%)
20% less capital invested
Capital invested by funds: $267K → $214K (-$53.3K)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$9.23K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$7 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$5.77K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.36K |
| 3 |
Two Sigma Advisers
New York
|
-$1.69K |
CELZ Hedge Fund Activity: Q3 2024 in Review
10 of the 6,977 institutional investors tracked by Wall St. Rank reported a position in Creative Medical Technology (CELZ) for Q3 2024, worth a combined $214K — down 20% from $267K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new CELZ positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 3 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $9.23K. The largest seller was Two Sigma Investments, cutting an estimated $5.77K.
- 10 institutional investors held Creative Medical Technology (CELZ) as of Q3 2024, up from 9 in Q2 2024.
- Funds reported $214K of Creative Medical Technology stock for Q3 2024, down 20% quarter-over-quarter.
- 1 fund opened new Creative Medical Technology positions in Q3 2024 and 0 closed out, a net change of +1 holder.
- The largest Creative Medical Technology buyer in Q3 2024 was UBS Group, an estimated $9.23K added.
- The largest Creative Medical Technology seller in Q3 2024 was Two Sigma Investments, an estimated $5.77K sold.
Based on aggregated 13F filings for Q3 2024.